GTN innovates a quantum machine learning technology to transform drug discovery.
Bringing a single new drug to the market costs $2.9bn, often delivering an intervention that barely differs from those already in the market. Projections into the future are not promising, with an expected 50% drop in R&D output every nine years.At GTN they are searching the astronomically large space of drug-like molecules with their unique patented technology, Generative Tensorial Networks. Their software combines and builds upon techniques from machine learning and quantum physics to simulate, filter and search for molecules, halving development costs and discovering molecules entirely hidden from view.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 4, 2018 | Seed | £2.10M | 1 | Octopus Ventures | — | Detail |
Jun 1, 2017 | Non-Equity Assistant | — | 1 | Google for Startups | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Octopus Ventures | Yes | Seed |
Google for Startups | Yes | Non-Equity Assistant |